Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors
illi News/10298948

~ At the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., presented groundbreaking research that could potentially revolutionize cancer treatment. The global biotech company, focused on developing treatments for disorders of the central nervous system (CNS) and cancer, shared their latest findings on novel orally bioavailable p300-selective degraders.

According to Ryan Kruger, Ph.D., Chief Scientific Officer at SK Life Science Labs, their research has shown that these selective p300 degraders have the potential to effectively shut down tumor growth in difficult-to-treat cancers while also reducing toxicity due to their precise targeting. This offers hope for the development of safer drug therapies for patients who currently have limited treatment options.

The p300 protein is known to play a role in driving various solid cancers. Through targeted p300 degraders, the team at SK Life Science Labs has demonstrated exceptional selectivity and potency in inhibiting tumor cell growth across multiple indications including castrate-resistant prostate cancer and cancers where the related protein CBP is missing or mutated. In preclinical studies, once daily oral administration of these potent p300-selective degraders resulted in rapid degradation of p300 and a significant reduction in tumor growth.

More on illi News

• Naperville: Bulk Brush Collection to Help Residents With Spring Yard Clean-Ups
• OpenSSL Technical Advisory Committee Elections Now Open – Cast Your Vote
• RallyCap Sports Launches New Illinois Chapter: Inclusive Sports Coming to Sheridan!
• Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
• Twitter's Buzzing! What's the Deal with PhotoG, the AI Everyone's Talking About?

One of the key advantages of using a heterobifunctional degrader to target p300 is its ability to generate molecules that can specifically target p300 over CBP with remarkable selectivity. Additionally, unlike other molecules currently in development that only suppress its activity, p300 degraders eliminate this critical protein required for cancer cells. This discovery highlights the potential for safer and more effective oncology therapies for some of the most challenging types of cancers.

For more information about SK Life Science Labs and their research on p300-selective degraders, interested parties can visit their website at www.sklslabs.com. The company also welcomes strategic alliance and partnership opportunities in their pursuit of developing innovative treatments for CNS disorders and cancer.

---

Show All News | Report Violation